Guideline / position statementindependent cross-checkfull text checked I-GUT-10 in-depth review
EULAR 2023 lupus treatment
EULAR recommendations for the management of systemic lupus erythematosus: 2023 update.
Overview
Fanouriakis A et al.. Ann Rheum Dis 2024 · PMID 37827694 · DOI 10.1136/ard-2023-224762
Hydroxychloroquine for all patients; immunosuppressants and biologics to control disease.
Does the study support the specific claim? No · Methodological quality: high
Plain-language summary
Study explained simply
- What did the researchers want to find out?
SLE treatment.
- How was the study done?
Guideline.
- What was actually found?
Drug-based management.
- What do the results mean in everyday life?
Lupus needs medical treatment.
- What are the study's limitations?
COI.
- What does it say about Elawady's specific claim?
Contradicts C-AUTO-01.
- Do the results apply to Germany and Europe?
Applicable.
Scientific in-depth review
1. Full reference
- Authors
- Fanouriakis A et al.
- Journal
- Ann Rheum Dis
- Year
- 2024
- Identifier
- PMID 37827694 DOI 10.1136/ard-2023-224762
- Verification
- verified – PubMed efetch 2026-10-25
- Retracted
- no
- Corrections
- none
- Extent checked
- full text
- Conflicts of interest and funding
Funded by EULAR (project QoC015). Most task-force members report honoraria, consulting fees, grants or advisory roles with pharmaceutical companies (incl. GSK, AstraZeneca, Otsuka, Novartis, Roche, Lilly, Janssen, Aurinia); one member holds stock in AstraZeneca, one in Aurinia.
2. Research question
How should systemic lupus erythematosus (general and organ-specific, incl. lupus nephritis) be managed in light of evidence published 2018-2022?
3. Study design and population
- Study design
- Guideline / position statement – Clinical practice guideline (EULAR 2023 update) developed per EULAR SOPs and AGREE II, based on five PICO-based systematic literature reviews, Oxford levels of evidence, and structured consensus voting
- Population
Patients with SLE (incl. lupus nephritis, cutaneous, neuropsychiatric, haematological disease, SLE-associated APS)
- Country
Europe/international (task force incl. members from the Americas, Asia and Australia)
- Period
SLRs of English-language publications Jan 2018 - Dec 2022 (building on evidence to Dec 2017 from the 2019 update); meetings April-May 2023
- Sample size
Task force of 35 rheumatologists, 5 nephrologists, 2 patient representatives, 2 methodologists and 2 fellows; 5 SLRs; 5 overarching principles and 13 recommendations
- Inclusion and exclusion criteria
PubMed and Cochrane CENTRAL; English language only; RCT RoB by Cochrane tool, observational studies by Newcastle-Ottawa
4. Methods and endpoints
- Exposure / intervention
Hydroxychloroquine, glucocorticoids, immunosuppressants (methotrexate, azathioprine, mycophenolate, cyclophosphamide), calcineurin inhibitors, biologics (belimumab, anifrolumab, rituximab); non-pharmacological measures
- Comparator
not applicable
- Endpoints
Recommendations with level of evidence, strength and level of agreement
- Statistical methods
Consensus voting (>75% first round, >66% second round); level of agreement 0-10
5. Actual results
- Results
HCQ recommended for all patients (target 5 mg/kg real body weight/day) and should not be discontinued without unacceptable adverse effects (associated with survival; discontinuation linked to flares); glucocorticoids as bridging, maintenance <=5 mg/day and withdrawal when possible; early immunosuppressants and/or biologics (belimumab 1a/A, anifrolumab 1a/A); active proliferative lupus nephritis: low-dose IV cyclophosphamide (1a/A) or mycophenolate (1a/A) plus glucocorticoids, with add-on belimumab or CNIs (1b/A), and treatment for at least 3 years after renal response. Overarching principle C: non-pharmacological interventions (sun protection, smoking cessation, healthy balanced diet, exercise, bone health) are important but not SLE-specific (LoA 9.90). Lupus nephritis is described as severe disease with increased morbidity and mortality leading to CKD.
- Absolute risks
not applicable
- Authors' conclusion
The updated recommendations provide consensus guidance on SLE management combining evidence and expert opinion.
6. Strengths
- Formal SOP/AGREE II process with predefined voting and graded evidence
- Multidisciplinary international panel including patient representatives and methodologists
- Very high agreement (most LoA >9/10)
7. Weaknesses
- Extensive industry relationships of panel members relevant to recommended biologics
- SLR limited to two databases and English language
- Some recommendations rest on expert opinion (level 4/C)
- No dietary intervention evidence reviewed; diet addressed only generically
8. Risk of bias
- Orienting tool
- none applicable (clinical practice guideline; AGREE II-oriented structured judgement)
- Type of assessment
- structured assessment based on the full text by a single reviewer (no formal double review)
- Full formal assessment
- no
- Overall risk of bias
- some concerns
- Rationale
No standard RoB tool for guidelines in this project; AGREE II-oriented single-reviewer judgement from full text, not formal. Core recommendations (HCQ, immunosuppression for nephritis) rest on level 1a evidence and are not plausibly driven by COI.
| Domain | Judgement | Rationale |
|---|---|---|
| Scope and purpose | low | Explicit PICO questions in five domains. |
| Stakeholder involvement | low | Rheumatologists, nephrologists, patient representatives, methodologists, international members. |
| Rigour of development | some concerns | Systematic reviews with RoB tools and Oxford grading, but restricted to English and two databases; consensus process for gaps. |
| Clarity of presentation | low | Recommendations with LoE, strength and LoA tabulated. |
| Editorial independence | some concerns | Funded by EULAR, but widespread panel COI with manufacturers of recommended drugs. |
Full-text review (25 October 2026): Added guideline methods (SOP/AGREE II, 5 SLRs 2018-2022, PubMed/CENTRAL, Oxford grading, voting thresholds), panel composition, evidence grades for key recommendations, HCQ non-discontinuation and survival, lupus nephritis regimens, the generic 'healthy balanced diet' principle, EULAR funding; AGREE II-oriented structured judgement (overall changed from not_assessable to some_concerns).
9. Assessment of the statistical interpretation
Not applicable (consensus guideline); key recommendations graded 1a/A.
10. Relevance to the specific claim
11. Independent contrary findings
12. Transferability to Germany and Europe
European.
13. Overall methodological judgement
Drug therapy (HCQ for all; immunosuppressants/biologics for active and organ-threatening disease, notably lupus nephritis) is the evidence-based standard of care; diet appears only as a generic healthy-lifestyle principle, not as a treatment for SLE.
| Multidimensional assessment | |
|---|---|
| Authenticity of the source | verified |
| Methodological quality | high |
| Risk of bias | some concerns |
| Precision of results | not applicable |
| Directness | direct |
| Reproducibility | unknown |
| Consistency with the overall evidence | consistent |
| Regional transferability | high |
| Adequacy of the interpretation (by the archive) | not applicable |
14. Open questions
Role of specific dietary interventions in SLE (not covered by this guideline).
15. Linked fact checks
- Autoimmune diseases such as multiple sclerosis and lupus are just recurrent inflammatory reactions to changing food inputs, arbitrarily grouped into disease names; lupus is treated by following the Tayebat system. – Studies contradicting or limiting the claim
- Eggs cause red cheeks that are misdiagnosed as lupus; a patient with lupus (including protein in the urine) would heal completely if she stopped eating eggs, instead of taking biological treatment. – Studies contradicting or limiting the claim